Figure 1: Total Global Disease Burden by Cause, 2017
Figure 2: Impact Analysis of Market Drivers and Market Challenges on Global Clinical Biomarkers Market
Figure 3: Share of Key Developments and Strategies, 2016-2019
Figure 4: Dominating Segments of the Global Clinical Biomarkers Market, 2019 and 2029
Figure 5: Global Clinical Biomarkers Market (by Product), 2019 and 2029
Figure 6: Global Clinical Biomarkers Market (by Clinical Area), 2019 and 2029
Figure 7: Global Clinical Biomarkers Market (by Technology), 2019 and 2029
Figure 8: Global Clinical Biomarkers Market (by End User), 2019 and 2029
Figure 9: Global Clinical Biomarkers Market (by Region), 2019 and 2029
Figure 2.1: Global Clinical Biomarkers Market Segmentation
Figure 3.1: Global Clinical Biomarkers Market Research Methodology
Figure 3.2: Primary Research Methodology
Figure 3.3: Bottom-Up Approach (Segment-Wise Analysis)
Figure 3.4: Top-Down Approach (Segment-Wise Analysis)
Figure 4.1: Global Clinical Biomarkers Market, 2018 and 2029 ($Billion)
Figure 5.1: Number of Deaths by Top 18 Infectious Diseases, 2015
Figure 5.2: Number of Deaths (in Million) by Different Forms of Cancer, 2018
Figure 6.1: Share of Key Developments and Strategies, 2016–2019
Figure 6.2: Synergistic Activities Share (by Company), 2016 – 2019
Figure 6.3: Product Approval Share (by Company), 2016 –2019
Figure 6.4: Product Launches and Upgrades Share (by Company), 2016 –2019
Figure 6.5: Mergers and Acquisitions Share (by Company), 2016 –2019
Figure 6.6: Market Share Analysis for the Global Clinical Biomarkers Market, 2018
Figure 6.7: Growth Share Matrix for Global Clinical Biomarkers Market (by Company), 2018
Figure 7.1: Global Clinical Biomarkers Market (by Type), 2018-2029 ($Billion)
Figure 7.2: Global Clinical Biomarkers Market for Diagnostic Biomarkers, 2018-2029 ($Billion)
Figure 7.3: Global Clinical Biomarkers Market for Predictive Biomarkers, 2018-2029 ($Billion)
Figure 7.4: Global Clinical Biomarkers for Prognostic Biomarkers, 2018-2029 ($Billion)
Figure 8.1: Global Clinical Biomarkers Market (by Clinical Area), 2018-2029 ($Billion)
Figure 8.2: Global Clinical Biomarkers Market for Cancer Biomarkers, 2018-2029 ($Billion)
Figure 8.3: Global Clinical Biomarkers Market for Breast Cancer Biomarkers, 2018-2029 ($Billion)
Figure 8.4: Global Clinical Biomarkers Market for Lung Cancer Biomarkers, 2018-2029 ($Billion)
Figure 8.5: Global Clinical Biomarkers Market for Colorectal Cancer Biomarkers, 2018-2029 ($Billion)
Figure 8.6: Global Clinical Biomarkers Market for Prostate Cancer Biomarkers, 2018-2029 ($Billion)
Figure 8.7: Global Clinical Biomarkers Market for Cardiac Biomarkers, 2018-2029 ($Billion)
Figure 8.8: Global Clinical Biomarkers Market for Neurological Biomarkers, 2018-2029 ($Billion)
Figure 8.9: Global Clinical Biomarkers Market for Infectious Disease Biomarkers, 2018-2029 ($Billion)
Figure 8.10: Global Clinical Biomarkers Market for Immunological Biomarkers, 2018-2029 ($Billion)
Figure 8.11: Global Clinical Biomarkers Market for Non-Invasive Prenatal Testing, 2018-2029 ($Billion)
Figure 8.12: Global Clinical Biomarkers Market for Other Clinical Areas, 2018-2029 ($Billion)
Figure 9.1: Global Clinical Biomarkers Market for Real Time PCR, 2018-2029 ($Billion)
Figure 9.2: Global Clinical Biomarkers Market for ELISA, 2018-2029 ($Billion)
Figure 9.3: Global Clinical Biomarkers Market for IHC, 2018-2029 ($Billion)
Figure 9.4: Global Clinical Biomarkers Market for NGS, 2018-2029 ($Billion)
Figure 9.5: Global Clinical Biomarkers Market for Other Technologies, 2018-2029 ($Billion)
Figure 10.1: Global Clinical Biomarkers Market (by End User)
Figure 10.2: Global Clinical Biomarkers Market (by End User), 2018-2029 ($Billion)
Figure 10.3: Global Clinical Biomarkers Market for Research and Academic Laboratories, 2018-2029 ($Billion)
Figure 10.4: Global Clinical Biomarkers Market for Biopharmaceutical and Biotech Companies, 2018-2029 ($Billion)
Figure 10.5: Global Clinical Biomarkers Market for Diagnostic Centres, 2018-2029 ($Billion)
Figure 10.6: Global Clinical Biomarkers Market for Other End Users, 2018-2029 ($Billion)
Figure 11.1: Global Clinical Biomarkers Market (by Region), 2019 and 2029 ($Billion)
Figure 11.2: Global Clinical Biomarkers Market (by Region), 2018-2029 ($Billion)
Figure 11.3: Global Clinical Biomarkers Market Share (by Region), 2018 ($Billion)
Figure 11.4: Global Clinical Biomarkers Market Share (by Region), 2029 ($Billion)
Figure 11.5: North America Clinical Biomarkers Market, 2018-2029 ($Billion)
Figure 11.6: North America Clinical Biomarkers Market (by Country), 2018-2029 ($Billion)
Figure 11.7: North America: Market Dynamics
Figure 11.8: The U.S. Clinical Biomarkers Market, 2018-2029 ($Billion)
Figure 11.9: Canada Clinical Biomarkers Market, 2018-2029 ($Billion)
Figure 11.10: Europe Clinical Biomarkers Market, 2018-2029 ($Billion)
Figure 11.11: Europe: Market Dynamics
Figure 11.12: Europe Clinical Biomarkers Market (by Country), 2018-2029 ($Billion)
Figure 11.13: Germany Clinical Biomarkers Market, 2018-2029 ($Billion)
Figure 11.14: U.K. Clinical Biomarkers Market, 2018-2029 ($Billion)
Figure 11.15: France Clinical Biomarkers Market, 2018-2029 ($Billion)
Figure 11.16: Italy Clinical Biomarkers Market, 2018-2029 ($Billion)
Figure 11 17: Spain Clinical Biomarkers Market, 2018-2029 ($Billion)
Figure 11.18: Rest-of-Europe Clinical Biomarkers Market, 2018-2029 ($Billion)
Figure 11.19: Asia-Pacific Clinical Biomarkers Market, 2018-2029 ($Billion)
Figure 11.20: APAC: Market Dynamics
Figure 11.21: APAC Global Clinical Biomarkers Market (by Country), 2018-2029 ($Billion)
Figure 11.22: China Clinical Biomarkers Market, 2018-2029 ($Billion)
Figure 11.23: Japan Clinical Biomarkers Market, 2018-2029 ($Billion)
Figure 11.24: India Clinical Biomarkers Market, 2018-2029 ($Billion)
Figure 11.25: Australia Clinical Biomarkers Market, 2018-2029 ($Billion)
Figure 11.26: Singapore Clinical Biomarkers Market, 2018-2029 ($Billion)
Figure 11.27: Rest-of-Asia Pacific Clinical Biomarkers Market, 2018-2029 ($Billion)
Figure 11.28: Latin America Clinical Biomarkers Market, 2018-2029 ($Billion)
Figure 11.29: Latin America: Market Dynamics
Figure 11.30: Latin America Clinical Biomarkers Market (by Country), 2018-2029 ($Billion)
Figure 11.31: Brazil Clinical Biomarkers Market, 2018-2029 ($Billion)
Figure 11.32: Mexico Clinical Biomarkers Market, 2018-2029 ($Billion)
Figure 11.33: Rest-of-Latin America Clinical Biomarkers Market, 2018-2029 ($Billion)
Figure 11.34: RoW Clinical Biomarkers Market, 2018-2029 ($Billion)
Figure 12.1: Total Number of Companies Profiled
Figure 12.2: Abbott Laboratories: Overall Product Portfolio
Figure 12.3: Abbott Laboratories: Overall Financials, 2016-2018
Figure 12.4: Abbott Laboratories: Revenue (by Segment), 2016-2018
Figure 12.5: Abbott Laboratories: Revenue Split for Diagnostics, 2016-2018
Figure 12.6: Abbott Laboratories: Revenue (by Region), 2016-2018
Figure 12.7: Abbott Laboratories: R&D Expenditure, 2016-2018
Figure 12.8: Abbott Laboratories: SWOT Analysis
Figure 12.9: Agilent Technologies, Inc.: Overall Product Portfolio
Figure 12.10: Agilent Technologies, Inc.: Overall Financials, 2017-2019
Figure 12.11: Agilent Technologies, Inc.: Revenue (by Segment), 2017-2019
Figure 12.12: Agilent Technologies, Inc.: Revenue (by Region), 2017-2019
Figure 12.13: Agilent Technologies, Inc.: R&D Expenditure, 2017-2019
Figure 12.14: Agilent Technologies, Inc.: SWOT Analysis
Figure 12.15: ALCEDIAG: Overall Product Portfolio
Figure 12.16: ALCEDIAG: SWOT Analysis
Figure 12.17: Becton, Dickinson and Company: Overall Product Portfolio
Figure 12.18: Becton, Dickinson and Company: Overall Financials, 2017-2019
Figure 12.19: Becton, Dickinson and Company: Revenue (by Segment), 2017-2019
Figure 12.20: Becton, Dickinson and Company: Revenue (by Sub-Segment – BD Life Sciences), 2017-2019
Figure 12.21: Becton, Dickinson and Company: Revenue (by Region), 2017-2019
Figure 12.22: Becton, Dickinson and Company: R&D Expenditure, 2017-2019
Figure 12.23: Becton, Dickinson and Company: SWOT Analysis
Figure 12.24: bioMérieux S.A.: Overall Product Portfolio
Figure 12.25: bioMérieux S.A.: Overall Financials, 2016-2018
Figure 12.26: bioMérieux S.A.: Revenue (by Segment), 2016-2018
Figure 12.27: bioMérieux S.A.: Revenue (by Region), 2016-2018
Figure 12.28: bioMérieux S.A.: R&D Expenditure, 2016-2018
Figure 12.29: bioMérieux S.A.: SWOT Analysis
Figure 12.30: Bio-Rad Laboratories, Inc: Overall Product Portfolio
Figure 12.31: Bio-Rad Laboratories, Inc.: Overall Financials, 2016-2018
Figure 12.32: Bio-Rad Laboratories, Inc.: Sales (by Segment), 2016-2018
Figure 12.33: Bio-Rad Laboratories, Inc.: Sales (by Region), 2016-2018
Figure 12.34: Bio-Rad Laboratories, Inc.: R&D Expenditure, 2016-2018
Figure 12.35: Bio-Rad Laboratories, Inc.: SWOT Analysis
Figure 12.36: CENTOGENE N.V.: Overall Product Portfolio
Figure 12.37: CENTOGENE N.V.: Overall Financials, 2016-2018
Figure 12.38: CENTOGENE N.V.: Sales (by Segment), 2016-2018
Figure 12.39: CENTOGENE N.V.: Sales (by Region), 2016-2018
Figure 12.40: CENTOGENE N.V.: R&D Expenditure, 2016-2018
Figure 12.41: CENTOGENE N.V.: SWOT Analysis
Figure 12.42: F. Hoffmann-La Roche Ltd.: Overall Product Portfolio
Figure 12.43: F. Hoffmann-La Roche Ltd.: Overall Financials, 2016-2018
Figure 12.44: F. Hoffmann-La Roche Ltd.: Sales (by Segment), 2016-2018
Figure 12.45: F. Hoffmann-La Roche Ltd.: Sales (by Region), 2016-2018
Figure 12.46: F. Hoffmann-La Roche Ltd.: R&D Expenditure, 2016-2018
Figure 12.47: F. Hoffmann-La Roche Ltd.: SWOT Analysis
Figure 12.48: Enzo Biochem Inc.: Overall Product Portfolio
Figure 12.49: Enzo Biochem Inc.: Overall Financials, 2017-2019
Figure 12.50: Enzo Biochem Inc.: Revenue (by Segment), 2017-2019
Figure 12.51: Enzo Biochem Inc.: Revenue (by Region), 2017-2019
Figure 12.52: Enzo Biochem Inc.: R&D Expenditure, 2017-2019
Figure 12.53: Enzo Biochem Inc.: SWOT Analysis
Figure 12.54: Hologic, Inc.: Overall Product Portfolio
Figure 12.55: Hologic, Inc.: Overall Financials, 2017-2019
Figure 12.56: Hologic, Inc.: Sales (by Segment), 2017-2019
Figure 12.57: Hologic, Inc.: Sales (by Region), 2017-2019
Figure 12.58: Hologic, Inc.: R&D Expenditure, 2017-2019
Figure 12.59: Hamilton, Inc.: SWOT Analysis
Figure 12.60: Illumina, Inc: Overall Product Portfolio
Figure 12.61: Illumina, Inc.: Overall Financials, 2016-2018
Figure 12.62: Illumina, Inc.: Sales (by Segment), 2016-2018
Figure 12.63: Illumina, Inc.: Sales (by Region), 2016-2018
Figure 12.64: Illumina, Inc.: R&D Expenditure, 2016-2018
Figure 12.65: Illumina, Inc.: SWOT Analysis
Figure 12.66: Myriad Genetics, Inc.: Overall Product Portfolio
Figure 12.67: Myriad Genetics, Inc.: Overall Financials, 2017-2019
Figure 12.68: Myriad Genetics, Inc.: Sales (by Segment), 2017-2019
Figure 12.69: Myriad Genetics, Inc.: R&D Expenditure, 2017-2019
Figure 12.70: Myriad Genetics, Inc.: SWOT Analysis
Figure 12.71: Quest Diagnostics Incorporated, Inc.: Overall Product Portfolio
Figure 12.72: Quest Diagnostics Incorporated: Overall Financials, 2016-2018
Figure 12.73: Quest Diagnostics Incorporated.: Sales (by Segment), 2016-2018
Figure 12.74: Quest Diagnostics Incorporated: SWOT Analysis
Figure 12.75: QIAGEN N.V.: Overall Product Portfolio
Figure 12.76: QIAGEN N.V.: Overall Financials, 2016-2018
Figure 12.77: QIAGEN N.V.: Revenue (by Segment), 2016-2018
Figure 12.78: QIAGEN N.V.: Revenue (by Region), 2016-2018
Figure 12.79: QIAGEN N.V.: R&D Expenditure, 2016-2018
Figure 12.80: QIAGEN N.V.: SWOT Analysis
Figure 12.81: Thermo Fisher Scientific Inc.: Overall Product Portfolio
Figure 12.82: Thermo Fisher Scientific Inc.: Overall Financials, 2016-2018
Figure 12.83: Thermo Fisher Scientific Inc: Sales (by Segment), 2016-2018
Figure 12.84: Thermo Fisher Scientific Inc.: Sales (by Region), 2016-2018
Figure 12.85: Thermo Fisher Scientific Inc.: R&D Expenditure, 2016-2018
Figure 12.86: Thermo Fisher Scientific Inc.: SWOT Analysis